RETENTION: TWO METHODS

RETENTION: TWO METHODS Date: March 6, 1995 New York University Medical Center is isolated on the edge of Manhattan's affluent Kip's Bay neighborhood, an area that includes only sparse pockets of subsidized lower- and middle- income housing. According to Kay Ryan, director of clinical trials development for the center, "Here, the patient population is not more than half minority, and here we have to do something to recruit minorities." "Something," in NYU's case, is recruiting pa

Written byM. E. W.
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

New York University Medical Center is isolated on the edge of Manhattan's affluent Kip's Bay neighborhood, an area that includes only sparse pockets of subsidized lower- and middle- income housing. According to Kay Ryan, director of clinical trials development for the center, "Here, the patient population is not more than half minority, and here we have to do something to recruit minorities."

"Something," in NYU's case, is recruiting patients for its cancer trials from Bellevue Hospital Center, the large municipal hospital next door that serves much of mid- and downtown Manhattan's minority and poor population, and from the Manhattan Veterans Administration Hospital several blocks away, for recruitment into the cancer center's many studies, says outreach coordinator Caron Bowen. She cites other problems they face: Some of the patients are homeless; others are barely meeting the rent. This creates what she calls "issues of compliance."

"We do try to find creative ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies